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Abstract 
Protocols which permit the extraction of primary astrocytes from either embryonic or 
postnatal mice are well established however astrocytes in culture are different to those in 
the mature CNS. Three dimensional (3D) cultures, using a variety of scaffolds may 
enable better phenotypic properties to be developed in culture.  We present data from 
embryonic (E15) and postnatal (P4) murine primary cortical astrocytes grown on coated 
coverslips or a 3D polystyrene scaffold, Alvetex. Growth of both embryonic and postnatal 
primary astrocytes in the 3D scaffold changed astrocyte morphology to a mature, 
protoplasmic phenotype. Embryonic-derived astrocytes in 3D expressed markers of 
mature astrocytes, namely the glutamate transporter GLT-1 with low levels of the 
chondroitin sulphate proteoglycans, NG2 and SMC3.  Embroynic astrocytes derived in 
3D show lower levels of markers of reactive astrocytes, namely GFAP and mRNA levels 
of LCN2, PTX3, Serpina3n and Cx43. Postnatal-derived astrocytes show few protein 
changes between 2D and 3D conditions. Our data shows that Alvetex is a suitable 
scaffold for growth of astrocytes, and with appropriate choice of cells allows the 
maintenance of  astrocytes with the properties of mature cells and  a non-reactive 
phenotype.  
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Introduction 
Astrocytes are important cells of the central nervous system (CNS) with a wide range of 
properties [1-3]. Functions ascribed to astrocytes include supplying neurons with lactate, 
uptake and conversion of L-glutamate to glutamine [4-7], and secretion of glutathione in 
response to the generation of reactive oxygen species [8]. They control the composition 
of the extracellular microenvironment [9], and regulate blood flow through control of local 
vasculature [10]. Astrocytes also influence synaptic function through potassium uptake, 
mainly though Kir 4.1 [11] and glutamate uptake [12].  Astrocytes change their 
phenotype in response to CNS injury in an incompletely-understood process called 
reactive astrogliosis. Reactive astrogliosis in vivo, encompasses a variety of 
phenotypical and morphological changes in astrocytes which occur over time and differ 
dependent on the type of injury [13]. The main hallmark of gliosis is an increase in levels 
of the intermediate filament protein, glial fibrillary acidic protein (GFAP), a protein almost 
exclusively enriched in astrocytes [14] which appears as a thickening of intermediate 
filaments, allowing reactive astrocytes to be distinguished from quiescent astrocytes in 
tissue sections [15, 16]. Reactive astrocytes can protect or exacerbate ongoing neuronal 
pathology [17-20]. In some human neurodegenerative diseases and animal models of 
disease, reactive astrocytes with elevated GFAP show a loss of the abundant excitatory 
amino acid transporter 2 (EAAT2, also known as GLT-1 in rodent species) [21, 22]. 
Transcriptomic analysis in different pathological models show that astrocytes have 
distinct gene expression profiles under different types of CNS insult [13] with a range of 
proteins beyond GFAP and EAAT2 that are regulated.  
Whilst in vivo research shows consistent data regarding astrocyte phenotype in different 
pathological models, progress is limited by cell models.  In vitro models yield astrocytes 
which are partially representative of cells in the adult brain [23, 24]. Such preparations 
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yield astrocytes lacking their key transport and metabolic proteins and their characteristic 
protoplasmic morphology [23]. Mechanical (trituration) or chemical (trypsin) based 
dissociation also yields astrocytes which express very high levels of GFAP [25]. In 
addition, pure astrocyte cultures lack the neuronal interactions which regulate phenotype 
of astrocytes in vivo, for example  culture of astrocytes without neurones causes 
reduction in expression of EAAT-2/GLT-1 [22]. 
There have been recent developments in creating new in vitro models to study the 
function of astrocytes. Scaffolds have been used to recreate aspects of the 3 
dimensional arrangement of astrocytes in vitro, for example using collagen [26, 27], 
hydrogels [12, 28], tripalmitin [29] and poly-ε-caprolactone electrospun scaffolds [28, 30, 
31]. In this study, we report the use of Alvetex, a commercially available porous scaffold 
formed of polystyrene that is supplied as cell culture inserts of 200µm thickness [32]. 
Here we report some of the phenotypic features of astrocytes grown in this way 
compared to conventional two-dimensional (2D) cultures. We compared astrocytes 
cultured using two different techniques: cultured from embryonic mice, using a method 
that was developed in this lab that preserves the adult astrocyte marker EAAT2/GLT-1 
expression on cultured astrocytes [21], and the more commonly used method to culture 
astrocytes from postnatal brains and re-plate [22, 33, 34].  
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Experimental Procedures 
Animal Groups and cell preparation 
Timed mated female NIH Swiss mice and P4 NIH Swiss neonates (Harlan UK) were 
euthanized in accordance with the UK Animals (Scientific Procedures) Act (1986). 
Animals were killed using cervical dislocation, according to Home Office guidelines. 
Cerebral cortices from E15 mouse embryos (embryonic) or P4 pups (postnatal) were 
obtained and cells were isolated via mechanical dissociation as previously described 
[35]. The cell suspension was centrifuged (5 min, 200g) and re-suspended in the 
appropriate media (see below).  
For embryonic astrocyte cultures, cells were plated in astrocyte specific media 
(DMEM/F-12 (HAM) GIBCO® Astrocyte Medium – Life Technologies) supplemented 
with glucose (33mM), L-Glutamine (2mM), 10% FBS  and sodium bicarbonate (13mM) 
(all other reagents obtained from Life Technologies).   
For postnatal (P4) astrocyte cultures, the cerebral cortices were dissected and triturated 
in 1 x HBSS containing L-glutamate (2mM), penicillin (100units/mL) and streptomycin 
(0.1 mg/mL) (all reagents obtained from Life Technologies). The supernatant was 
removed and tissues were mixed with 2ml Earle’s balanced salt solution (EBSS – 
Containing 20 units/ml Papain and 0.5mM EDTA (Sigma)), 10µl of DNAse 1 (20,000 
Units, Life Technologies) and incubated at 37°C for 15 minutes. The mixture was further 
triturated with MEM complete medium containing L-Glutamine (2mM), FBS (10%), 
penicillin (100units/mL) and streptomycin (0.1 mg/mL) supplemented with bovine serum 
albumin (BSA, Sigma) and trypsin inhibitor (ovomucoid - 1mg/ml respectively, Sigma). 
The remaining cell suspension was mixed with 5ml of MEM (without BSA and 
ovomucoid), centrifuged at 1500RPM for 7 minutes and the resulting pellet plated in 
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DMEM containing L-Glutamine (2mM), FBS (10%), penicillin (100units/mL) and 
streptomycin (0.1 mg/mL) into 175 cm2 flasks pre-coated with poly-D-lysine (0.1mg/ml, 
Sigma) allowing 2 cortices per flask. Cells were cultured for 18-21 days after which 
microglia were shaken off in an orbital shaker (200 RPM for 5 hours) and the remaining 
astrocytes were washed with PBS (37°C) and trypsinsed using 0.25% trypsin-EDTA for 
5 minutes (Life technologies) and seeded into 6 or 12 well plates. After a further 3 DIV, 
cells were harvested for experimental use. 
Two-dimensional Cell Culture system 
13mm glass coverslips (0.13mm thick, VWR International Ltd, Lutterworth, UK) were 
coated with poly-L ornithine (1.5µg/mL solution, Sigma, Dorset, UK) for 24 hours. 
Afterwards, coverslips were washed with sterile phosphate buffered saline (PBS, , Life 
Technologies, Paisley, UK) supplemented with glucose (33mM), penicillin (100units/mL) 
and streptomycin (0.1 mg/mL) (reagents from Life Technologies), and incubated in 
serum containing medium (10% foetal bovine serum (FBS), Labtech, Uckfield, UK) for 2 
hours 37°C and 5% CO2 before plating. Embryonic or postnatal cells were plated at 
density of 8 x 105 cells/mL into 6 well plates or 4 x 105 cells/mL onto coverslips in 12 well 
plates and maintained for 10-12 d (embryonic) or 3d (postnatal) in the appropriate 
growth media.. After 10-12 days in vitro (DIV), 2D primary cortical astrocyte controls 
were 90-100% confluent. 
Three-dimensional cell Culture system 
In order to grow cells in three-dimensions (3D), we used a 200µm thick polystyrene 
scaffold: Alvetex® (Reinnervate, Durham, UK). We used both 6 well (AVP004-3, 22mm 
diameter, Reinnervate) and 12 well (AVP005-3, 15mm diameter, Reinnervate) in-well 
inserts to grow cells in 3D. To render the scaffold hydrophilic, inserts were first fully 
7 
 
submerged in 70% ethanol for 10 minutes. The inserts were then washed twice with 
sterile water and then incubated with poly-L-ornithine (1.5µg/ml) for 24 hours. After 
coating, the inserts were washed with PBS and finally incubated in serum containing 
media for two hours at 37°C and 5% CO2 before plating cells.   
Embryonic or postnatal cells were plated on pre-coated Alvetex (Reinnervate, Durham, 
UK, see below for details of pretreatment) either  into 6 well plates containing Alvetex®  
inserts at a density of  8x105 cells per mL  or into 12 well plates containing Alvetex® 
inserts at a density of at 4 x105 cells/mL. Inserts were seeded by applying the cell 
suspension to the top of the membrane.  
Immunofluorescence and cell characterisation 
To characterize cell morphology, cells on coverslips and in Alvetex were fixed using 4% 
paraformaldehyde (PFA; 30 min at room temperature, Sigma) dissolved in PBS; blocked 
and permeabilised in 1% normal goat serum (NGS, Labtech) and 0.2% Triton-X (Sigma) 
in PBS, for 1 hour at room temperature (22°C). For GFAP fluorescence, cells were 
incubated with a mouse polyclonal GFAP primary antibody (Dako, Ely, UK. 1 in 2000) in 
PBS containing 1% NGS (PBS/NGS) overnight (~18hrs) at 4°C. Cells were further 
incubated with a secondary antibody conjugated to Alexafluor 488 (in PBS/NGS, 2µg/ml 
- Invitrogen; Life Technologies), for 90 minutes at room temperature (22°C). After 90 
minutes, cells were washed and incubated with Hoescht 33342 (4µg/ml – 5 minutes; Life 
Technologies) and mounted on microscope slides using Vectashield (Vector 
Laboratories, Peterborough, UK).  
Images were collected on an inverted spinning disc confocal (Zeiss Axiovert 200M) 
microscope connected to an LSM 510 laser scanning module (Zeiss) and diode 
(Coherent). 10x/20x and 40x Plan-NeoFluar objectives were used and images were 
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collected using a colour camera (Zeiss AxioCam HRc colour camera) and processed 
using Volocity software. High resolution images were created using Photoshop CS3. 
Proliferation and MTT Turnover 
E15 and P4 astrocytes were seeded into 12 well plates onto treated plastic or Alvetex 
scaffold. We monitored MTT turnover as previously described [35]. In short, cells were 
washed with HBM buffer (4.76 g HEPES, 40.88 g NaCl, 0.372 g KCl, 0.42 g NaHCO3, 
0.1654 g NaH2PO4, 0.3 g Glucose and 240 µl of 0.5 M CaCl2 (Sigma)) and further 
incubated with 500µl of MTT buffer per well (0.5 mg/ml Thiazoyl Blue Tetrazolium 
Bromide (Sigma) in HBM) at 37°C for 1 h. The formazide precipitate (MTT) was then 
solubilised with 300 µl DMSO (Fisher Scientific, Loughborough, UK) per well and the 
plate was left on a benchtop orbital shaker at 150RPM for 5 minutes. 200 µl from each 
well was transferred to a 96 well plate and absorbance was measured using a plate 
reader (Flexstation 3, Molecular Devices. λ = 490 nm). 
Western Blotting 
Western blotting was carried out in accordance to methods previously described [21, 35, 
36]. In short, cells were lysed in lysis buffer (50mM Tris, 150mM NaCl, 1% Triton-X, all 
obtained from Sigma) containing a mini EDTA free protease inhibitor tablet (in 10ml of 
lysis buffer – Roche Applied Science, Burgess Hill, UK). We used primary rabbit 
polyclonal antibodies for GFAP (DAKO), GLT-1 (provided by Prof. David Pow, RMIT 
University, 1:5000 (0.04 µg/ml)) and Glutamine Synthetase (Abcam - ab49873, 1µg/ml) 
as cytoskeletal, transport and metabolic indicators of ‘reactivity’. Monoclonal goat anti 
mouse GAPDH (clone 6C5, 1:10000 (0.1µg/ml) - per 10µG protein load; Life 
technologies) was used as a reference protein. Primary antibodies were incubated 
overnight at 4°C in TTBS (20mM Tris buffer (pH 7.5 - Sigma) containing 0.4% Tween-20 
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(Sigma) and 1% non-fat milk powder). PVDF membranes were washed in TTBS and 
incubated with goat anti rabbit/goat anti mouse secondary antibodies conjugated to 
horseradish peroxidase (HRP – 1:5000 - Sigma) at room temperature (22°C) for 1 hour. 
After washing, membranes were further incubated with ECL reagent (Clarity, Biorad, 
Hemel Hempstead, UK) for 2 minutes. The ECL reagent was prepared according to 
manufacturer’s protocol. Membranes were imaged using the Chemidoc MP imaging 
system (Biorad) for chemiluminescence and analysed by the corresponding ImageLab 
software (Biorad). Images were exported from the software at a resolution of 300dpi into 
photoshop CS3 and used for representation.  
qPCR – Reactive Markers 
RNA was extracted using RNA Bee (AMS Biotechnology, Abingon, UK). All RNA 
samples were collected from cells growing in 6 well plates on poly-L-ornithine treated 
plastic or Alvetex scaffold (8 x 105 cells per well). RNA Bee was added to each well (1 
ml) on ice for 5 minutes. RNA was extracted in accordance to the manufacturer’s 
protocol. RNA concentrations were calculated using a NanoDrop 2000 
spectrophotometer (Thermo Scientific, Warrington, UK). A high capacity cDNA kit 
(4368814 - Life Technologies) was used to transcribe 1 µg of RNA. To perform PCR, the 
cDNA reaction mixture was diluted 1:20 in Tris-EDTA buffer (Sigma) and 5µl of cDNA 
was combined with 2 μl of both the forward and reverse primers (2.5 μM stock, final 
concentration 100 nM) and 7µl SYBR green (#170-8880 - Biorad). Oligonucleotide 
sequences were designed using the Primer3 website [37] and ordered through Sigma. 
Mus musculus LCN2/Serpina3n and connexin 43  were amplified using PCR and the 
following sets of oligonucleotides: LCN2 (F) 5’- ATGGCCCTGAGTGTCATGTG-3’ 
(bases 23-43) and (R) 5’- ATGGCCCTGAGTGTCATGTG-3’ (bases 162-182 - fragment 
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size 139 base pairs) based on first published sequence [38] (NCBI Accession number 
NM_008491.1).  
Serpina3n (F) 5’- TGATGAGCATGGAGGACCTG -3’ (bases 827-847) and (R) 5’- 
CTTCCACCTGCTGCATCTTG -3’ (bases 964-984 - fragment size 138 base pairs) 
primers were designed based on original published sequences [39] (NCBI Accession 
number NM_009252.2). Connexin43 (F) 5’-GTCCCACGGAGAAAACCATC -3’ (bases 
837-857) and (R) 5’-GATCGCTTCTTCCCTTCACG-3’ (bases 968-988 - fragment size 
132 base pairs) primers were designed based on original published sequences [40] 
(NCBI Accession number NM_010288.3). GFAP (F) 5’-TTTCTCCAACCTCCAGATCC -
3’ (bases 1223-1243) and (R) 5’-GGTGAGCCTGTATTGGGACA -3’ (bases 1335-1355 - 
fragment size 132 base pairs) primers were designed based on original published 
sequences [41] (NCBI Accession number NM_010277.3). Primer sequences for GLT-1 
((F) 5’-GCCAACAATATGCCCAAGCAG -3’ (bases 10-30) and (R) 5’- 
GACACCAAACACAGTCAGTGA -3’ (bases 153-133 - fragment size 144 base pairs)) 
were obtained from Primerbank (ID: 227330634c1) and ordered through Sigma. F+R 
denote forward and reverse primers. Primers were re-suspended in nuclease free water, 
to a concentration of 2.5μM. We used the Stepone Plus qPCR system (Applied 
Biosystems part of Life technologies) to assay changes in mRNA. CT values were 
exported from the software and comparative analysis was carried using relative 
quantification (RQ).  
Statistical Analysis 
Statistical comparison of treatment groups was carried out using unpaired students t-test 
unless otherwise stated (Prism 6, GraphPad Software, CA, USA). 
Results 
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Astrocytes change shape when cultured in 3D scaffolds 
Astrocytes were derived from NIH Swiss mouse embryos (E15) and postnatal (P4) mice. 
Embryonic cells were seeded directly onto coated glass coverslips or activated Alvetex 
and maintained for 12 days before experimental use. Postnatal cells were cultured in 
flasks for 18-21 days, trypsinised and re-plated onto coated glass coverslips or activated 
Alvetex scaffold. After 3 DIV, postnatal cells were either fixed or lysed for appropriate 
experiments. Astrocytes were characterized using epifluorescent microscopy, 
counterstaining for GFAP. Embryonic astrocytes have limited processes with small cell 
bodies close to each other in 2D (glass coverslip), (Fig 1,A). Postnatal astrocytes, have 
a more protoplasmic morphology in 2D (Fig 2, A). When cultured in Alvetex, the 
morphology changes for both embryonic and postnatal astrocytes, with astrocytes 
adopting a more protoplasmic phenotype (Fig 1, E; Fig 2, E).  
Embryonic cells were plated at the same time and same density either into the scaffold 
or in 2D. We observed reduced mitochondrial succinate dehydrogenase activity (50% 
MTT turnover compared to 2D, data not shown) in the scaffold compared to 2D 
indicating reduced cell viability or cell number. Both embryonic-derived and postnatal-
derived astrocytes grown in Alvetex have longer processes which stretch through the XZ 
plane (Fig 1H and Fig 2H), appear larger in size and are present throughout the scaffold. 
In 3D, cells show greater spreading which we attribute to the increased surface area of 
the Alvetex scaffold (Fig 1 E). Importantly, the scaffold can be imaged using Differential 
Interference Contrast (DIC) microscopy and cells can be visualized inside the scaffold 
(Fig 1, E+F and Fig 2 E+F). 
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Postnatal-derived astrocytes contain more microglia (not shown). Trypsinised postnatal 
astrocytes are much more robust, with many cells seeding into the scaffold (80% MTT 
turnover compared to 2D, data not shown). 
Expression of astrocyte markers in embryonic cultures changes in 3D scaffolds 
We next characterized the expression of a number of astrocyte markers, comparing 3D 
Alvetex cultures to the conventional 2 dimensional cultures, with both embryonic and 
postnatal-derived astrocytes. 
For astrocytes derived from E15 embryos, the expression of some of the main astrocyte 
hallmarks was decreased in 3D in comparison to 2D cultures (Fig, 3). Using Western 
blotting, we compared 3D astrocytes to their 2D controls. Interestingly, we observed 
lower GFAP expression in 3D embryonic astrocytes compared to 2D controls (53 ± 8% 
reduction, p < 0.05, n = 3). Levels of GLT-1 were significantly lower in 3D embryonic 
astrocytes compared to 2D controls (36 ± 7% reduction, p < 0.05, n = 3). Furthermore, 
another glutamate transporter, glutamate-aspartate transporter (GLAST) was found at 
significantly reduced levels in 3D cultured astrocytes (64 ± 1% reduction, p < 0.05, n = 
3). Levels of a key metabolic enzyme enriched in astrocytes, glutamine synthetase (GS), 
remained the same whether embryonic-derived cultures were grown in Alvetex or on 
glass coverslips.  
Other markers of astrocytes were measured including the chondroitin sulphate 
proteoglycans (CSPGs) SMC3 [42] and NG2 [43] (Fig. 3). Both proteins were found in 
embryonic-derived astrocytes grown in 2D. In embryonic-derived astrocytes grown in 
3D, SMC3 was undetectable and levels of NG2 were significantly lower than found in 2D 
cultures (70 ± 7% reduction, p < 0.001, n = 3). 
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Next we assayed mRNA levels to identify differences between 3D and 2D cultures from 
embryonic-derived astrocytes (Fig. 5A). Supporting the differences in protein levels, 
astrocytes in 3D cultures displayed reduced levels of GFAP (0.8 fold reduction ± 0.01, p 
≤ 0.001, n = 3) and GLT-1 (0.8 fold reduction ± 0.01, p ≤ 0.001, n = 3) compared to 2D 
cultures. We also assayed some transcripts recently identified as being highly regulated 
during astrogliosis [13]. We chose LCN2 (lipocalin 2), serpina3n (serine (or cysteine) 
peptidase inhibitor, clade A, member 3N), PTX3 (pentraxin 3) and Cx43 (connexin 43). 
Embryonic cultures in 3D have lower mRNA levels compared to 2D controls for LCN2, 
Serpina3n, PTX3 and Cx43 (0.8 fold reduction ± 0.1 for all genes, n = 3)  
Astrocyte markers in postnatal cultures show few differences when cultured in 3D 
scaffolds 
In comparison to embryonic-derived astrocytes, astrocytes derived from postnatal CNS 
showed similar expression in both 2D and 3D cultures for nearly all proteins analyzed 
(Fig 4.). A key difference between postnatal-derived and embryonic-derived astrocytes is 
that there was negligible GLT-1 expression in postnatal-derived astrocyte cultures. The 
predominant glutamate transporter in postnatal astrocytes is GLAST and no difference 
was found between 3D and 2D cultures. In addition, the levels of GS, GFAP and NG2 
were the same between postnatal astrocytes grown in 3D compared to 2D.  The level of 
SMC3 was significantly lower in 3D cultures compared to 2D cultures (89 ± 6% 
decrease, p < 0.001, n = 3).  
Using qPCR we assayed the expression profile of the reactive markers described above 
(Fig 5.). Postnatal-derived astrocytes grown in 3D displayed significantly increased 
levels of LCN2 (1.8 fold increase ± 0.3, p < 0.05, n = 3) and significant decreases in both 
PTX3 (0.5 fold reduction ± 0.1, p < 0.05, n = 3) and Cx43 (0.6 fold reduction ± 0.1, p < 
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0.01, n = 3). Levels of GFAP and GLT-1 did not change between 2D and 3D cultures. 
Levels of Serpina3n were increased in 3D (0.9 fold increase ± 0.3, n = 3), although this 
increase was not statistically significant (p = 0.0509). 
Discussion 
Astrocyte culture is a well-established technique necessary to understand the biology of 
these important cells and to provide an in vitro counterpart to in vivo models. Several 
groups have shown that culture of cells on 3D scaffolds can enhance astrocyte 
phenotype, indicative of a less ‘reactive’ expression profile [26, 30]. For first time we 
tested a commercially available material, Alvetex as a 3D scaffold.  We chose this 
material because it is easy to prepare compared to collagen gels or fibers which require 
electrospinning, and Alvetex is reported to be physiologically inert. We sought to identify 
whether culturing in the scaffold alone could change the phenotype of astrocytes which 
had been derived from either embryonic or postnatal mice. To do this, we monitored the 
expression of the main astrocyte hallmarks finding differences for GLT-1, GFAP and 
GLAST in embryonic cultures along with CSPG markers of immature glia and some 
novel putative markers of reactive astrocytes. In summary, our results showed that 
astrocytes derived from embryonic tissues expressed markers of mature astrocytes 
when grown in either 2D or 3D, namely GFAP, GS and GLT-1. When grown in 3D, 
embryonic-derived astrocytes showed lower levels of expression than their 2D 
counterparts of GFAP and mRNA levels of a number of genes associated with reactive 
astrogliosis, namely LCN2, serpina3N, PTX3 and Cx43.  In contrast, astrocytes derived 
from postnatal CNS expressed GFAP and GS but not GLT-1.  Unlike primary astrocytes 
derived from embryonic tissue, these cultures, when grown in Alvetex did not show a 
profile associated with reduced reactivity, with some markers increasing and others 
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decreasing. Astrocytes derived from postnatal tissue importantly, lack a key transporter 
protein found in mature astrocytes, namely GLT-1. 
One of the key findings is that in Alvetex, primary astrocytes derived from embryonic 
tissue displayed a morphology which is more similar to mature astrocytes in intact 
tissues than found in astrocytes grown on coverslips.  Specifically, astrocytes grown on 
coverslips display a cobblestone like morphology, while in Alvetex the cells are smaller 
and have fine processes, supporting recent findings [29]. These differences in shape are 
accompanied by lower expression of GFAP. We associate a reduced GFAP with a less 
reactive phenotype: in vivo, astrocytes have low levels of GFAP unless there is CNS 
injury [15]. In addition to reduced GFAP, there are reduced levels of a number of 
transcripts encoding markers that have recently been associated with a reactive 
phenotype. Whilst these astrocytes are derived from embryonic tissue, they display a 
mature phenotype, including expression of GLT-1, an abundant protein in adult 
astrocytes and also low levels of the CSPGs NG2 and SMC3. 
We have a particular interest in expression and regulation of the glutamate transporter, 
GLT-1 [27, 44] that is responsible for approximately 95% of all L-glutamate uptake in the 
CNS and accounts for about 1% of all CNS protein [5, 45, 46]. Recent transcriptomic 
data, confirms that GLT-1 is predominantly enriched in astrocytes [14, 45, 47]. It is 
known that GLT-1 expression is influenced by neuronal growth factors and the 
expression of GLT-1 declines in astrocytes during culture [48]. We have previously 
developed our embryonic-derived astrocyte culture in order to preserve expression of 
GLT-1, and the data confirms that these astrocytes support GLT-1 expression both in 2D 
and 3D culture.  In contrast postnatal-derived astrocytes, which are re-plated and grown 
longer in culture (25 DIV in total, compared to 10-12 DIV for the embryonic-derived 
cultures), show negligible expression of GLT-1, though these cells maintain robust 
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expression of GLAST, a related transporter which accounts for less than 5% of all 
glutamate uptake in the mature CNS. These results support observations that cortical 
astroglial culture yields distinct populations of astrocytes depending on the method and 
age of the mice. Embryonic (E13-16) culture yields astrocytes rich in GLT-1, though 
confluent cells in 2D lose protoplasmic processes and have elevated levels of GFAP. In 
these cultures GLT-1 is lost over time in culture unless supplemented with G-5 
supplement (EGF, FGF, Transferrin, Hydrocortisone, Selenite, Insulin, Biotin) which 
increases RNA and protein levels of both GLT-1 and GLAST [49]. Postnatal cortical 
astrocytes tend to grow as mixed glial cell populations, mainly astrocytes but with a 
higher proportion of microglia. Such cultures take longer to become confluent and whilst 
they too express high levels of GLAST; GLT-1 levels decrease over time, with the 
functional burden of glutamate transport assumed by GLAST  [48, 50]. Indeed, research 
has shown that GLAST mediates the majority of L-glutamate uptake in postnatal cortical 
astrocyte cultures (28-35 DIV), correlating with increased cell surface expression of 
GLAST [22]. 
We also note that expression levels of GLT-1 were lower in embryonic-derived cultures 
grown in 3D compared to 2D. These results suggest the intriguing notion that reduced 
astrocyte reactivity is associated with lower levels of GLT-1. In disease or animal 
disease models, under conditions where astrocytes up-regulate GFAP there is often 
down-regulation of GLT-1 eg in Motor Neuron Disease [22, 30, 51]. Loss of GLT-1 
during astrocyte reactivity is often associated with a loss of protective functions in 
astrocytes.  Specifically, astrocyte GLT-1 loss has been linked to excitotoxic neuronal 
death in some disorders, particularly Motor Neuron Disease e.g [23-25, 52]. In this study 
we show that GLT-1 and GFAP expression appear to be co-regulated.  The Alvetex 
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system provides an experimental platform to enable the study of astrocyte reactivity and 
co-regulation of GFAP and GLT-1. 
In vitro, astrocytes have a high replicative capacity, another feature of gliosis. The latter 
stages of gliosis involve replication of immature reactive astrocytes and deposition of 
extracellular matrix proteins in an attempt to provide a physical barrier to any areas of 
insult in the brain [15, 46]. Rich in this region are CSPG’s, a family of different core 
proteins that differ in their glycosaminoglycan motifs [52]. CSPG’s fall into 4 main 
families with a range of functions in health and disease [53]. CSPG upregulation is a 
consequence of reactive astrogliosis and a feature of glial scarring. [54, 55]. We note 
that embryonic-derived astrocytes grown in 3D have low levels of the 2 CSPGs we 
measured, NG2 and SMC3, further support for these conditions supporting a less 
reactive, more physiologically representative phenotype.  For postnatal-derived 
astrocytes, CSPGs were well expressed both in 2D and 3D cultures suggesting that 
these cultures have a more reactive phenotype that may be associated with their 
capacity for cell division. 
We note recent evidence that the rho-kinase inhibitor Fasudil regulates astrocyte 
morphology through the re-distribution of actin, potentiating a neuroprotective astrocyte 
phenotype [56, 57]. Other work has shown that inhibition of the Rho-ROCK axis inhibits 
CSPG induced myosin phosphatase phosphorylation and reverses coffilin 
phosphorylation [58, 59] showing that CSPG and ROCK interaction regulate astrocyte 
morphology. 
Differences between embryonic-derived and postnatal-derived astrocyte cultures are 
found in terms of morphology, GLT-1 and CSPG expression. Relative quantification of 
qPCR data revealed that postnatal cultures also have a different mRNA expression 
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profile in 2D and 3D compared to embryonic-derived cultures. Unlike embryonic-derived 
astrocytes, where all transcripts analyzed were lower in 3D culture compared to 2D 
culture, postnatal-derived astrocytes had higher  LCN2 and serpina3n mRNAs in 3D 
compared to 2D, and unchanged GLT-1 and GFAP mRNA. Transcriptomic analysis of 
astrocytes obtained from two different injury models identified these genes as hallmarks 
of reactive astrocytes, particularly LCN2 which was upregulated greater than 200 fold in 
each model [13]. Interestingly, only LCN2 and serpina3n increase, whereas PTX3 and 
Cx43 remain very low. 
As well as the protein and mRNA changes already discussed, there were differences in 
MTT turnover, indicating differences in cell viability or numbers in the Alvetex®, 
compared to cultures plated in 2D, even though cells were plated at the same densities. 
We believe this is due to non-adherence of cells to the scaffold, rather than toxicity.  
Alternatively the scaffold may inhibit cell division. Indeed, astrocyte culture with a 3D 
collagen scaffold has also shown a reduction in cell viability  [26]. In this set of 
experiments, we did not look at the levels of NOTCH expression which may determine 
differences in proliferation in astrocytes [60, 61]. Further work will clarify these points in 
more detail.  The differences in gene expression, protein expression and shape that we 
observe could potentially be attributed to culture confluency.  We tested seeding at 
different densities onto Alvetex and did not observe any phenotypic or expression 
differences which related to cell viability as shown in Figure 3 (GFAP & GAPDH lanes) 
and data not shown, and attribute the differences we observe to the scaffold rather than 
the cell density. Further investigation would required to compare 3D and 2D cultures at 
the same cell densities, and we note that that this is difficult to control for, since the 
scaffold itself complicates quantifying cell numbers. 
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In conclusion in this study we show for the first time that Alvetex scaffolds are a suitable 
support for primary astrocyte cultures.  We show that astrocytes display a less reactive 
phenotype than found on standard coverslips as evaluated by morphology and a range 
of biochemical markers. Furthermore we demonstrate that astrocytes derived from 
embryonic cerebral cortex have more of the phenotypic properties of mature, non-
reactive astrocytes than astrocytes derived from postnatal brain that are passaged.  
Altogether this work suggests some technical advances to standardization and use of 
astrocyte cultures to understand astrogliosis and astrocyte function. 
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Figure Legends 
Figure 1 
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Immunohistochemistry showing GFAP expression (green) in embryonic 2D (A-D) and 3D 
(E-H) cultures. Embryonic derived cells were seeded directly onto glass (2D) or Alvetex® 
(3D) scaffolds and maintained for 12 DIV (days in vitro). DIC microscopy permits 
visualisation of the Alvetex scaffold (E). 3 dimensional isosurface images of 2D (glass 
coverslip) (B+C) and 3D (Alvetex scaffold) (F+G) show number, shape and size of cells. 
XZ plots (D+H) show the Z plane. Embryonic-derived cells are found throughout the full 
width of the 3D scaffold. Nuclei are counterstained with Hoescht 33342 (blue). Scale 
bars = 10µm.  
Figure 2 
Immunohistochemistry showing GFAP expression (green) in postnatal-derived 2D (A-D) 
and 3D (E-H) cultures. Postnatal derived cells were trypsinised after 21 DIV (days in 
vitro), re-plated onto glass (2D) or Alvetex® (3D) scaffolds and maintained for a further 3 
DIV. 3D isosurface images rendered in 2D (glass coverslip) (B+C) and 3D (Alvetex) 
(F+G) show number, shape and size of cells. XZ plots (D+H) show the Z plane, note that 
cells are found throughout the full width of the 3D scaffold. Nuclei are counterstained 
with Hoescht 33342 (blue). Scale bars = 10µm. 
 
Figure 3 
Western blotting was carried out for a number of protein markers of astrocytes using 
protein samples from embryonic-derived cultures (12 DIV). Panel (A) shows glutamate 
transporter (GLT-1: trimer 160 kDa and monomer 65 kDa), glutamine synthetase (GS, 
45KDa).  Lower blot shows glial fibrillary acidic protein (GFAP, 50 kDa). * indicates 
samples derived from cells plated at double the density. Glyceraldehyde Phosphate 
Dehydrogenase (GAPDH) was used as a sample loading control. Panel (B) shows 
glutamate transporter (GLAST: timer 160KDa, monomer 55 kDa) and the CSPGs SMC3 
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(140 KDa) and NG2 (250kDa). Panel (C) shows quantification of Western signals, first 
normalised to GAPDH, with the 3D levels expressed as a % of the 2D levels derived 
from parallel cultures. GLT-1, GFAP, GLAST, NG2 but not GS are found at reduced 
levels, with SMC3 levels too low to be quantified. Statistical analysis was carried out 
using student’s t –test (* = p<0.05, **= p<0.01, ***=p<0.001). N = 3 independent cultures 
 
Figure 4 
Western blotting was carried out for a number of protein markers of astrocytes using 
protein samples from postnatal-derived cultures (25 DIV). Panel (A) shows glutamate 
transporter (GLAST: trimer 160 kDa and monomer 55 kDa), the CSPGs SMC3 (140 
KDa) and  NG2 (250kDa), glutamine synthetase (GS, 45KDa) and glial fibrillary acidic 
protein (GFAP, 50kDa).  Glyceraldehyde Phosphate Dehydrogenase (GAPDH) was 
used as a sample loading control. Panel (B) shows glutamate transporter (GLT-1: trimer 
160 kDa and monomer 65 kDa), which was barely detectable in most samples.  Panel 
(C) shows quantification of Western signals, first normalised to GAPDH, with the 3D 
levels expressed as a % of the 2D levels derived from parallel cultures. SMC3 but not 
NG2, GLAST or GS are found at reduced levels(***=p<0.001, students t-test). N = 3 
independent cultures 
 
Figure 5 
qPCR reveals differences in transcript levels of reactive markers in embryonic and 
postnatal 3D cultures when compared to their representative 2D controls. Graphs show 
RQ values represented as fold mRNA change on the y axis. Error bars represent SEM 
(n =3). GAPDH was used as a reference gene during relative quantification of CT 
values. (A) Embryonic-derived cultures have lower levels of LCN2, Serpina3N, GFAP, 
GLT-1, PTX3 and Cx43 measured when cultured in the 3D scaffold (*** = p<0.001, 
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Student’s T test). B) For postnatal-derived cultures, LCN2 shows a significant increase in 
3D whereas PTX3 and Cx43 show significant decreases in 3D scaffolds. GLT-1 and 
GFAP transcripts remain unchanged (* = p<0.05, ** = p<0.01, Student’s T test).    
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